Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • Publication number: 20190255026
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 22, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII
  • Publication number: 20190209599
    Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).
    Type: Application
    Filed: March 13, 2019
    Publication date: July 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji INAGAKI, Naoki MATSUMOTO, Toshihiro OGAWA, Yukihisa WAKABAYASHI, Asuka KAMIMURA, Yoshihiro OSHITA, Hitoshi NAKAZAWA, Isao MATSUOKA
  • Patent number: 10278985
    Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: May 7, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji Inagaki, Naoki Matsumoto, Toshihiro Ogawa, Yukihisa Wakabayashi, Asuka Kamimura, Yoshihiro Oshita, Hitoshi Nakazawa, Isao Matsuoka
  • Publication number: 20190105310
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi Kawata, Noriko Kawabata
  • Publication number: 20190106393
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • Publication number: 20190106748
    Abstract: Provided is a method for measuring an Alu RNA level in blood by (1) carrying out a reverse transcription reaction on RNA extracted from a blood sample collected from a subject as a template, using a reverse transcription primer having a poly dT sequence and a universal tag sequence at the 5? side of the poly dT sequence, to synthesize cDNA, and (2) carrying out PCR amplification on the cDNA synthesized in step (1) as a template, using a forward primer consisting of a nucleotide sequence comprising at least 15 contiguous nucleotides from a nucleotide sequence consisting of nucleotides at positions 1 to 117 in the nucleotide sequence as set forth in SEQ ID NO: 1 and a reverse primer consisting of a complementary sequence to the universal tag sequence or a partial sequence thereof, and measuring an Alu RNA level based on an amount of the amplification product.
    Type: Application
    Filed: March 24, 2017
    Publication date: April 11, 2019
    Applicant: Santen Pharmaceutical Co., Ltd
    Inventor: Tokiyoshi Matsushita
  • Patent number: 10206815
    Abstract: The purpose of the present invention is to provide an injector for an intraocular lens, whereby it is possible to easily set a lens support part to an appropriate position on a lens holder, and to safely carry out insertion work. A lens holder (404) is provided with a base part (441), a release-side guide part (442), and a passing part (443). A concave part (450) for housing the tip of a first lens support part (92) is formed on the release-side guide part (442). The concave part (450) holds the first lens support part (92) above the passing part (443). The release-side guide part (442) guides the first lens support part (92) along the circumference of an optical part (91).
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 19, 2019
    Assignee: Santen Pharmaceutical Co., Ltd
    Inventors: Yoshitaka Yamada, Katsuyuki Ueno, Takashi Tanaka
  • Publication number: 20190038598
    Abstract: A pharmaceutical composition includes dorzolamide or a salt thereof and brimonidine or a salt thereof and has a pH of 6.0 or more. The pharmaceutical composition preferably does not include a preservative or includes a prescribed amount thereof, wherein said prescribed amount is preferably such that the common logarithmic value of the ratio (B/A) of the number (B) of bacteria at the time of inoculation to the number (A) of bacteria when the number of viable bacteria is measured after inoculating bacteria in a test sample that consists of the preservative and water and mixing homogeneously such that the concentration of Escherichia Coli ATCC 8739 in the bacterial suspension is within the range of 105-106 cfu/mL, and collecting 1 mL of the test sample using a micropipette after the test sample has been stored for seven days at 20-25° C. while shielded from light, is 2.0 or less.
    Type: Application
    Filed: February 21, 2017
    Publication date: February 7, 2019
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventor: Shinya UMEZAKI
  • Patent number: 10189796
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 29, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Yusuke Yamazaki, Shinji Takaoka, Daisuke Shii, Tomoko Oda, Takahiro Matsuyama
  • Patent number: 10179127
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: January 15, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Patent number: 10166217
    Abstract: For preventing or treating keratomycosis, a medicament containing rapamycin or a salt thereof as an active ingredient is used.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: January 1, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Jinzhong Zhang, Masaaki Kageyama
  • Publication number: 20180353531
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20180353518
    Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Applicants: Santen Pharmaceutical Co., LTD., Asahi Glass Company, Limited
    Inventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
  • Patent number: 10149908
    Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: December 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventor: Yoko Endo
  • Patent number: 10143761
    Abstract: A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: December 4, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda
  • Publication number: 20180311152
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Application
    Filed: November 7, 2017
    Publication date: November 1, 2018
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Publication number: 20180289618
    Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 11, 2018
    Applicants: Santen Pharmaceutical Co., Ltd., Asahi Glass Co., LTD.
    Inventors: Timo REUNAMAKI, Pertti PELLINEN, Olli OKSALA, Kari LEHMUSSAARI
  • Publication number: 20180271841
    Abstract: For preventing or treating keratomycosis, a medicament containing rapamycin or a salt thereof as an active ingredient is used.
    Type: Application
    Filed: September 13, 2016
    Publication date: September 27, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Jinzhong ZHANG, Masaaki KAGEYAMA
  • Patent number: 10071113
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20180244633
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA